Coating With Chitooligosaccharides Enhances the Cytokine Induction of Listeria ivanovii–Based Vaccine Strain

• Published in: Journal of pharmaceutical sciences Vol. 108; no. 9; pp. 2926 - 2933
• Main Authors: Zhang, Xiang, Su, Lin, Huang, Huan, Jiang, Mingjuan, Liu, Sijing, Li, Yongyu, Liu, Ting, Zhou, Yuzhen, Tang, Tian, Mahdy, Safy Eidin, Wang, Chuan
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.09.2019
• Subjects: adjuvant; chitooligosaccharides; Listeria ivanovii; vaccine vector; PBS; LM; Ag85c; ESAT-6; COS; BCG; vaccine vector; chitooligosaccharides; LLO; Listeria ivanovii; DMEM; APC; LAMP-1; adjuvant; PEI; FBS; Mtb; SEM; LI
• ISSN: 0022-3549; 1520-6017
• DOI: 10.1016/j.xphs.2019.04.011

Listeria ivanovi (LI) is an available live bacterial vaccine vector. This work attempted to coat LI-based vaccine candidates (LI-Rv0129c) with chitooligosaccharides (COSs) as an adjuvant to enhance the cellular immune responses induced. COS-bacteria composite was achieved by mixing the bacteria suspension with equal volume of COS solution, and this process accompanied with the increase of bacteria superficial zeta potential and formation of special superficial configurations. COS coating improved the ratio swallowed by the macrophage-like RAW264.7 cells from 0.54% to 2.88% (p < 0.001). In vivo, the COS-coated LI-Rv0129c strain did elicit significantly higher specific CD4+ IFN-γ, CD4+ TNF-α or CD8+ IFN-γ secretion (0.91%, 1.00%, 0.30%, respectively) than naked LI-Rv0129c (0.32%, 0.38%, 0.07%, respectively) (p < 0.01). These results demonstrated that COS is a promising adjuvant to enhance the protective cellular immune responses induced by LI-based vaccine strains. Our work provided a notion for developing adjuvant for Listeria and other bacterial vector-based vaccines.